Fractyl Health, Inc. is a metabolic therapeutics company based in Burlington, MA, focused on pioneering new approaches for the treatment of type 2 diabetes (T2D) and obesity. Their mission is to defend humanity from metabolic disease by developing transformative therapies that target the root causes of T2D and obesity, with a vision to prevent and eliminate metabolic diseases.
The company's innovative therapies include Revita, an outpatient procedural therapy designed to modify duodenal dysfunction for metabolic health, and Rejuva, a novel gene therapy platform aimed at improving islet function in patients with T2D and obesity. Fractyl Health is dedicated to delivering these disease-modifying therapies to patients as broadly and rapidly as possible, with a focus on long-term remission and sustained weight maintenance.
Generated from the website
